Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice - PubMed (original) (raw)

. 2002 Jul 19;297(5580):403-5.

doi: 10.1126/science.1073354.

Affiliations

Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice

Catherine B Millar et al. Science. 2002.

Abstract

The mammalian protein MBD4 contains a methyl-CpG binding domain and can enzymatically remove thymine (T) or uracil (U) from a mismatched CpG site in vitro. These properties suggest that MBD4 might function in vivo to minimize the mutability of 5-methylcytosine by removing its deamination product from DNA. We tested this hypothesis by analyzing Mbd4-/- mice and found that the frequency of of C --> T transitions at CpG sites was increased by a factor of three. On a cancer-susceptible Apc(Min/+) background, Mbd4-/- mice showed accelerated tumor formation with CpG --> TpG mutations in the Apc gene. Thus MBD4 suppresses CpG mutability and tumorigenesis in vivo.

PubMed Disclaimer

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources